Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF) (2017 - 2026)

Crinetics Pharmaceuticals' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 25.41% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 27.47% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 39.68% from the prior year.
• Depreciation & Amortization (CF) advanced to $1.2 million in Q1 2026 per CRNX's latest filing, from $994000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q1 2026 and bottomed at $215000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $474000.0 (2024), against an average of $583294.1.
• Across the five-year window, Depreciation & Amortization (CF) slipped 6.52% in 2022 and surged 200.76% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $280000.0 in 2022, then slipped by 6.43% to $262000.0 in 2023, then jumped by 200.76% to $788000.0 in 2024, then advanced by 26.14% to $994000.0 in 2025, then grew by 16.7% to $1.2 million in 2026.
• Per Business Quant, the three latest CRNX Depreciation & Amortization (CF) figures stand at $1.2 million (Q1 2026), $994000.0 (Q4 2025), and $1.0 million (Q3 2025).